Diseases don’t really just strike locally, even though that’s how we often think of them — they affect networks throughout the body on even the smallest of levels. By helping to map intracellular protein interactions, Albert-Laszlo Barabasi hopes to trace disease tracks so better treatments can be devised.
How does the FDA stack up in terms of its European counterparts in getting new drugs and devices to market as quickly as possible? And what goes into the process of green-lighting them? Larry Brilliant interviews Peggy Hamburg.
Apollo 11 was approaching the moon, the astronauts were almost out of oxygen — but many moon boulders stood in way of landing. Would they make it? And how did Buzz Aldrin’s heart react to the stress? Jay Walker shows an amazing relic from the Library of Human Imagination.
Because Elizabeth Bonker was unable to speak due to autism, specialists assumed she was learning challenged. Far from the case: She’s a highly intelligent child who found her voice through writing award-winning poetry.
Think big, act local: Cincinnati gathered all its stakeholders together to overhaul its health care system, Todd Park reports. Is their effort a model for the future?
Eating his greens and having an iron will help Scott Jurek win ultramarathons, but the support of friends and family and a quest for great health also gave him a head start.
Chronic diseases are shaping up to be as deadly and pernicious than the infectious variety, even in developing nations. Sandeep Kishore of the Young Professionals Chronic Disease Network talks about how doctors should be trained to understand and counter root causes, including societal issues.
Poverty is a major risk marker for disease. Can prescribing social services help needy patients heal — and keep them healthy in the first place? Onie’s Health Leads team of volunteers provides the missing link between healthcare and social services.
There is a perfect storm of factors behind our national obesity crisis, say HBO’s John Hoffman and Judith Salerno of the Institute of Medicine of the National Academies. That doesn’t mean, however, that we can afford to give up tackling it.
Neurologist Jonathan Glass and neurosurgeon Nick Boulis of Emory University ask: Should acceptable risk levels for experimental treatments be recalibrated for the terminally ill who have no other options?